share_log

PMV Pharmaceuticals Doses First Patient In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt In TP53 Y220C-Positive Solid Tumors

Benzinga ·  Mar 27 08:10
PMV Pharmaceuticals Doses First Patient In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt In TP53 Y220C-Positive Solid Tumors
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment